Latest Conference Articles

June 25th 2017, 8:20pm

European Hematology Association Congress

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

June 25th 2017, 8:17pm

European Hematology Association Congress

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

June 25th 2017, 8:16pm

European Hematology Association Congress

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

June 25th 2017, 8:09pm

European Hematology Association Congress

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.

June 24th 2017, 11:21pm

European Hematology Association Congress

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

June 24th 2017, 11:19pm

European Hematology Association Congress

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

June 24th 2017, 10:46pm

European Hematology Association Congress

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

June 24th 2017, 10:30pm

European Hematology Association Congress

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

June 24th 2017, 9:11pm

European Hematology Association Congress

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.

June 24th 2017, 12:43am

European Hematology Association Congress

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

June 24th 2017, 12:36am

European Hematology Association Congress

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

June 23rd 2017, 11:51pm

European Hematology Association Congress

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

June 23rd 2017, 11:50pm

European Hematology Association Congress

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.

June 23rd 2017, 11:16pm

European Hematology Association Congress

Jorge E. Cortes, MD, discusses ongoing advances with FLT3 inhibitors in acute myeloid leukemia.

June 22nd 2017, 8:37pm

European Hematology Association Congress

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia.

June 17th 2017, 11:32pm

International Conference on Malignant Lymphoma

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

June 17th 2017, 11:04pm

International Conference on Malignant Lymphoma

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

June 17th 2017, 11:01pm

International Conference on Malignant Lymphoma

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

June 17th 2017, 10:35pm

International Conference on Malignant Lymphoma

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

June 17th 2017, 9:18pm

International Conference on Malignant Lymphoma

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.